4-[2-hydroxy-3-(N,N-dimethylamino)propoxy]aniline hydrochloride | 358978-12-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-[2-hydroxy-3-(N,N-dimethylamino)propoxy]aniline hydrochloride
• 英文别名: 4-[2-Hydroxy-3-(dimethylamino)propoxy]aniline hydrochloride；1-(4-amino-phenoxy)-3-dimethylamino-propan-2-ol hydrochloride；4-[3-N,N-dimethylamino-2-hydroxypropoxy]aniline hydrochloride；1-(4-aminophenoxy)-3-(dimethylamino)propan-2-ol;hydrochloride
• CAS: 358978-12-8
• 化学式: C₁₁H₁₈N₂O₂*ClH
• 分子量: 246.737
• InChiKey: RKALDJKOJAJFIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.99
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  58.7
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-[2-hydroxy-3-(N,N-dimethylamino)propoxy]aniline hydrochloride 在 hydrochloric acid diethyl ether 作用下， 以 1,4-二氧六环 、 甲醇 、 正丁醇 为溶剂， 反应 48.0h， 生成 4-Anilino-2-{4-[2-hydroxy-3-(N,N-dimethylamino)propoxy]anilino}-5-(imidazol-1-ylmethyl)pyrimidine
  参考文献：
  名称：

  “ Eenie-Meenie反应”。双氨基嘧啶的置换反应

  摘要：

  描述了一种新型的酸催化的嘧啶亲核取代反应，涉及醌-甲基化物类型的化学反应。可以耐受多种亲核试剂。类似的机制也适用于三环系统的合成。

  DOI：

  10.1016/s0040-4039(01)02362-0
• 作为产物：
  描述：

  1-dimethylamino-3-(4-nitro-phenoxy)-propan-2-ol hydrochloride 在 palladium 10% on activated carbon 氢气 作用下， 以 乙醇 为溶剂， 生成 4-[2-hydroxy-3-(N,N-dimethylamino)propoxy]aniline hydrochloride
  参考文献：
  名称：

  WO2006/76442

  摘要：

  公开号：

文献信息

• 2,4-diamino pyrimidine compounds having anti-cell proliferative activity
  申请人：AstraZeneca AB

  公开号：US06593326B1

  公开（公告）日：2003-07-15

  A pyrimidine derivative of formula (I): wherein: R1 is an optional substituent as defined within; Rx is selected from halo, hydroxy, nitro, amino, cyano, mercapto, carboxy, sulphamoyl, formamido, ureido or carbamoyl or a group of formula (Ib): A—B—C— as defined within; Q1 and Q2 are independently selected from aryl, a 5- or 6-membered monocyclic moiety; and a 9- or 10-membered bicyclic heterocyclic moiety; and one or both of Q1 and Q2 bears on any available carbon atom one substituent of formula (Ia) as defined within; and Q1 and Q2 are optionally further substituted; or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof; are useful as anti-cancer agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

  式（I）的嘧啶衍生物： 其中：R1是如定义的可选取代基；Rx选自卤素、羟基、硝基、氨基、氰基、巯基、羧基、磺胺基、甲酰胺基、脲基或氨基甲酰基或如定义的式（Ib）的基团：A—B—C—；Q1和Q2独立选自芳基、5-或6-成员单环基；和9-或10-成员双环杂环基；Q1和Q2中的一个或两个在任一可用碳原子上带有如定义的式（Ia）的取代基；Q1和Q2可进一步取代；或其药学上可接受的盐或体内水解酯；可用作抗癌剂；并描述了其制备方法和含有它们的药物组合物。
• 2,4-Diamino pyrimidine compounds having anti-cell proliferative activity
  申请人：Breault Anne Gloria

  公开号：US20050090493A1

  公开（公告）日：2005-04-28

  A pyrimidine derivative of formula (I) wherein, for example, R 1 is hydrogen, (1-6C)alkyl, (3-5C)alkenyl or (3-5C)alkynyl; Q 1 and Q 2 are independently selected from phenyl, naphthyl, indanyl and 1,2,3,4-tetrahydronaphthyl; and one or both of Q 1 and Q 2 bears on any available carbon atom one substituent of formula (Ia) [provided that when present in Q 1 the substituent of formula (Ia) is not adjacent to the —NH— link]; wherein, for example, X is CH 2 , O, S or NH; Y is H or as defined for Z; Z is OH, SH, NH 2 , (1-4C)alkoxy, (1-4C)alkylthio, —NH(1-4C)alkyl, —N[(1-4C)alkyl] 2 or —NH—(3-8C)cycloalkyl; n is 1, 2 or 3; m is 1, 2 or 3; and Q 1 and Q 2 may optionally bear other substituents selected, for example, from halogeno, (1-6C)alkyl, cyano and (2-4C)alkenyl; or a pharmaceutically-acceptable salt or in-vivo-hydrolysable ester thereof; are useful as anti-cancer agents; and processes for heir manufacture and pharmaceutical compositions containing them are described.

  公式（I）的嘧啶衍生物，其中，例如，R1为氢，（1-6C）烷基，（3-5C）烯基或（3-5C）炔基；Q1和Q2分别选自苯基，萘基，茚基和1,2,3,4-四氢萘基；Q1和/或Q2中的一个或两个在任何可用的碳原子上带有公式（Ia）的取代基[前提是当存在于Q1时，公式（Ia）的取代基不与—NH—连接相邻]；其中，例如，X为CH2，O，S或NH；Y为H或如Z所定义；Z为OH，SH，NH2，（1-4C）烷氧基，（1-4C）烷基硫醚，—NH（1-4C）烷基，—N[(1-4C）烷基]2或—NH—（3-8C）环烷基；n为1, 2或3；m为1, 2或3；Q1和Q2可以选择性地带有其他取代基，例如，卤代，（1-6C）烷基，氰基和（2-4C）烯基；或其药学上可接受的盐或体内水解酯；可用作抗癌剂；并描述了其制备方法和含有它们的药物组合物。
• Pyrimidine compounds
  申请人：——

  公开号：US20030149064A1

  公开（公告）日：2003-08-07

  Pyrimidine derivatives of formula (I) wherein: Q 1 and Q 2 are independently selected from aryl or carbon linked heteroaryl optionally substituted as defined within; and one of Q 1 and Q 2 or both Q 1 and Q 2 is substituted on a ring carbon by one group selected from sulphamoyl, N—(C 1-4 alkyl)sulphamoyl (optionally substituted by halo or hydroxy), N,N-di-(C 1-4 alkyl)sulphamoyl (optionally substituted by halo or hydroxy), C 1-4 alkylsulphonyl (optionally substituted by halo or hydroxy) or a substituent of the formula (Ia) or (Ia′): wherein Q 1 , Q 2 , G, R 1 , Y, Z, Q 3 , n and m are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) inhibitors are also described.

  式(I)中的嘧啶衍生物，其中： Q1和Q2分别选自芳基或碳链杂芳基，如定义中所述，且Q1和Q2中的一个或两个在环碳上被选自磺酰氨基、N-(C1-4烷基)磺酰氨基（可选择地被卤素或羟基取代）、N,N-二-(C1-4烷基)磺酰氨基（可选择地被卤素或羟基取代）、C1-4烷基磺酰基（可选择地被卤素或羟基取代）或式(Ia)或(Ia′)的取代基之一取代：其中Q1、Q2、G、R1、Y、Z、Q3、n和m如定义中所述；描述了其药学上可接受的盐和体内可水解酯。还描述了其制备方法、药物组合物及其用作细胞周期依赖性丝氨酸/苏氨酸激酶（CDK）抑制剂的用途。
• 2,4-diamino-pyrimidine deprivatives having anti-cell proliferative activity
  申请人：AstraZeneca AB

  公开号：US06716831B1

  公开（公告）日：2004-04-06

  A pyrimidine derivative of formula (I) or (I′): wherein: Rx is a substituent as defined within; Q1 is optionally substituted phenyl, and Q1 bears a substituent of formula (Ia) wherein: X, Y1, Y2, Z, n, and m are as defined within; —NQ2 is an optionally substituted heterocyclic moiety containing one hydrogen heteroatom and optionally containing a further heteroatom; or a pharmaceutically acceptable salt in vivo hydrolysable ester thereof; are useful as anti-cancer agents. Processes for their manufacture and pharmaceutical compositions containing them are described.

  公式（I）或（I'）的嘧啶衍生物：其中：Rx是定义内的取代基；Q1是可选取代的苯基，并且Q1带有式（Ia）的取代基，其中：X，Y1，Y2，Z，n和m如定义内；—NQ2是可选取代的杂环基，含有一个氢杂原子，且可选含有另一个杂原子；或其体内可水解酯的药学上可接受的盐；可用作抗癌剂。描述了其制造过程和含有它们的制药组合物。
• PYRIMIDINE COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1161428B1

  公开（公告）日：2003-05-28